seragy holding GmbH (formerly Prosperodes GmbH) is a Hanover-based biomarker strategy company focused on neurodegenerative diseases and other proteopathies such as Alzheimer's, Parkinson's and ALS. Its proprietary SeRAS platform amplifies traces of misfolded protein seeds from patient samples and turns them into quantitative molecular fingerprints that reveal disease subtypes, giving pharmaceutical and biotechnology partners translational biomarkers for targeted drug development from discovery through clinical development. Founded in 2022 as Prosperodes, the holding company owns the intellectual property and licensing functions, while operations run through its wholly owned subsidiary seragy analytics GmbH.
1
Round
1
Industry
5
Tags
Oct 14, 2026
Latest raise
Funding activity · 1 round
Oct 14, 2026
EUR 12M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
